Minbos shares fire up as company progresses towards DFS stage

|

Published 01-SEP-2020 11:48 A.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Shares in Minbos Resources Limited (ASX:MNB) traded 20% higher on Tuesday morning after management announced that as part of its Cabinda Phosphate Definitive Feasibility Study (DFS), the had signed a contract with the FEECO International for the basic engineering package associated with the planned granulation plant major equipment.

Minbos won an international tender for the Cabinda Phosphate Project in March 2020.

Along with its in-country partner Soul Rock Ltda (15% carried interest), Minbos won the tender based on producing Enhanced Phosphate Rock as a substitute for fertilisers currently imported by the Angolan Government for distribution to wholesalers and farmers.

The endgame is the development of a nutrient supply and distribution business that provides food security to Angola and the broader Middle African region.

Coronavirus increases spotlight on the need for food security

The timing of this project couldn’t be better with the global-focused Food and Agricultural Organisation (FAO) recently highlighting that the strengthening of food production and distribution systems is the key to fighting hunger, and in turn, addressing disease issues that are affecting the world.

Bloomberg recently reported "as many as 132 million more people than previously projected could go hungry in 2020, and this year’s gain may be more than triple any increase this century".

Food supply issues are being exacerbated by COVID-19, which is projected to cause more people to die each day from hunger than from virus infections.

The FAO said that the world is ‘’hurtling towards an unprecedented hunger crisis exacerbated by the impact of coronavirus’’ as it has upended food supply chains, crippling economies and eroding consumer purchasing power.

In part, the FAO said, ‘’Some projections show that by the end of the year, Covid-19 will cause more people to die each day from hunger than from virus infections.’’

As the following map shows, the African region continues to struggle and it will be one of the hardest hit in terms of food security, making it most in need of projects such as those being developed by Minbos.

Working towards definitive feasibility study

Harking back to the precursor activities to a DFS, the contracted organisation FEECO provides industry-leading detailed plant engineering and manufacturing to the fertiliser and agriculture industry, constructing complete fertiliser systems for turnkey production facilities, including bulk material handling, granulation technology and control systems.

As part of management’s plans to build a nutrient supply and distribution business in Angola, 500 kilograms of Cabinda phosphate rock was supplied to the International Fertiliser Development Centre’s (IFDC) one-of-a-kind fertiliser pilot plant complex in Muscle Shoals, Alabama.

During August 2019, the IFDC performed one week of pilot plant trials and granulation testing to help determine the technical and financial feasibility of manufacturing and blending, producing 400 kilograms of Cabinda Blend, which is currently being used for in-country field trials.

FEECO is preparing a basic engineering package as part of the major equipment supply package, one of the essential elements in completing the upcoming DFS that will build on results of the Cabinda Phosphate Project Scoping Study released last week which demonstrated the project to be technically and financially robust.

The plus/minus 35% scoping study estimated an after-tax NPV of between US$159 - 260 million based on a pre-production capital estimate of between US$22 – 28 million.

As indicated below, Minbos has made substantial progress in other areas of planning, and with the basic engineering package running through to the December quarter, the company is approaching key milestones that could well be market moving.

Consequently, while the company’s shares have increased three-fold in the last three weeks, there is the potential for more upside, particularly given that the recent spike has only captured the inherent value of the step-change in the company’s progress, being the completion of the Cabinda Scoping Study.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X